Biotech Values

[DewDiligence]

PFE reports 3Q24 results—raises_2024_guidance_for Paxlovid, non-GAAP EPS:

https://s28.q4cdn.com/781576035/files/doc_financials/2024/q3/Q3-2024-PFE-Earnings-Release-Final.pdf


3Q24 highlights

• 3Q24 revenue was $17.7B, +32% YoY.

• 3Q24 oncology sales were $4.0B, +30% YoY, including an $854M contribution from former SGEN products.

• 3Q24 Comirnaty and Paxlovid sales were $1.4B and $2.7B, respectively; both products benefitted from a mid-summer spike in COVID infections.

• 3Q24 GAAP and non-GAAP EPS were $0.78 and $1.06, respectively. (3Q23 GAAP and non-GAAP EPS were losses.)


2024 full-year guidance

• 2024 revenue guidance is now $61-64B, up from the prior guidance of $59.5-62.5B, given three months ago. The $1.5B increase in revenue guidance is due to a $2B increase for Paxlovid (from to $3.5B to $5.5B), and a $500M decrease for all other products, largely due to the withdrawal from the market of Oxbryta.

• 2024 non-GAAP EPS guidance is now $2.75-2.95, up $0.30 at both ends from the guidance given three months. (Both the old and the new guidance ranges include a negative $0.40 hit from SGEN, most of which stems from the net interest expense on the $43B of net debt PFE took on to fund the acquisition.)

• 2024 Comirnaty sales guidance is $5B, unchanged from the guidance three months ago.


3Q24 CC slides:
https://investors.pfizer.com/files/doc_financials/2024/q3/Q3-2024-Earnings-Charts_FINAL.pdf

3Q24 CC prepared remarks (synched with slides):
https://s28.q4cdn.com/781576035/files/doc_financials/2024/q3/Q3-2024-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf